See more : Consilium Acquisition Corp I, Ltd. (CSLMR) Income Statement Analysis – Financial Results
Complete financial analysis of Ascendis Health Limited (ASC.JO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ascendis Health Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Helix BioMedix, Inc. (HXBM) Income Statement Analysis – Financial Results
- Suzhou Industrial Park Heshun Electric Co., Ltd. (300141.SZ) Income Statement Analysis – Financial Results
- Breeze Holdings Acquisition Corp. (BREZR) Income Statement Analysis – Financial Results
- Bolloré SE (BOIVF) Income Statement Analysis – Financial Results
- TLD3 Entertainment Group, Inc. (TLDE) Income Statement Analysis – Financial Results
Ascendis Health Limited (ASC.JO)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.ascendishealth.com
About Ascendis Health Limited
Ascendis Health Limited, a health and wellness company, manufactures and distributes healthcare products in South Africa, Cyprus, Spain, Hungary, Romania, and internationally. The company operates through Consumer Health, Pharma, and Medical segments. It offers body and skin products; and natural supplements, multi-vitamin and mineral supplements, micronutrient supplements, nutraceutical supplements, vitamins, minerals, and homeopathic and herbal products under the Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce brand names. The company also provides medical devices, and diagnostic laboratory equipment and consumables for operating theatres, ICUs, trauma units, maternity and general wards, radiology, pathology labs, research and science institutes, etc.; generic pharmaceutical products, antineoplastic agents, antivirals, aromatase inhibitors, anti-infectives; and products for the nervous system, cardiovascular system, dermatological products, and antimalarials, as well as other therapeutic products under the Pharmachem, Reuterina, Sinucon, Clonam, Phlexy, Surgical Innovations, RCA, and The Scientific Group brands. In addition, it exports its products. The company serves pharmacies, retailers, beauticians, and doctors. Ascendis Health Limited was incorporated in 2008 and is based in Johannesburg, South Africa.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.47B | 1.54B | 1.56B | 2.23B | 6.96B | 5.57B | 7.74B | 6.44B | 3.92B | 2.82B | 1.62B | 597.44M |
| Cost of Revenue | 886.86M | 930.91M | 921.72M | 1.30B | 3.75B | 3.19B | 4.27B | 3.62B | 2.36B | 1.59B | 890.10M | 339.93M |
| Gross Profit | 585.18M | 604.53M | 637.73M | 930.68M | 3.21B | 2.39B | 3.47B | 2.81B | 1.56B | 1.23B | 727.85M | 257.51M |
| Gross Profit Ratio | 39.75% | 39.37% | 40.89% | 41.75% | 46.12% | 42.86% | 44.85% | 43.71% | 39.87% | 43.62% | 44.99% | 43.10% |
| Research & Development | 0.00 | 0.00 | 0.00 | 1.29M | 463.00K | 14.36M | 13.29M | 36.26M | 2.49M | 0.00 | 0.00 | 0.00 |
| General & Administrative | 361.22M | 474.12M | 472.36M | 670.78M | 1.19B | 1.37B | 1.34B | 1.09B | 709.65M | 502.29M | 502.89M | 179.59M |
| Selling & Marketing | 88.80M | 102.77M | 113.90M | 167.19M | 669.81M | 587.56M | 769.06M | 615.32M | 326.66M | 291.52M | 46.83M | 19.26M |
| SG&A | 461.51M | 576.89M | 586.25M | 837.97M | 1.86B | 1.95B | 2.11B | 1.70B | 1.04B | 793.80M | 549.72M | 198.85M |
| Other Expenses | 0.00 | 3.57M | 17.23M | 41.00M | 18.93M | 52.84M | 16.95M | 14.32M | 78.68M | 24.16M | 51.42M | 8.83M |
| Operating Expenses | 461.51M | 784.82M | 824.16M | 1.05B | 2.65B | 2.50B | 2.55B | 2.11B | 1.26B | 891.59M | 565.25M | 213.66M |
| Cost & Expenses | 1.35B | 1.72B | 1.75B | 2.35B | 6.40B | 5.68B | 6.82B | 5.73B | 3.62B | 2.48B | 1.46B | 553.59M |
| Interest Income | 6.46M | 6.34M | 4.38M | 3.52M | 8.43M | 3.10M | 11.25M | 32.24M | 32.97M | 24.23M | 25.59M | 6.87M |
| Interest Expense | 12.48M | 62.47M | 431.25M | 1.05B | 809.53M | 363.58M | 347.44M | 306.33M | 163.48M | 93.30M | 53.71M | 52.98M |
| Depreciation & Amortization | 57.05M | 76.40M | 73.51M | 81.34M | 143.63M | 244.68M | 270.77M | 174.72M | 83.76M | 60.27M | 30.60M | 9.29M |
| EBITDA | 109.90M | -140.09M | -241.37M | -389.99M | -759.85M | -1.04B | 713.73M | 899.17M | 435.62M | 396.12M | 246.54M | 68.84M |
| EBITDA Ratio | 7.47% | -6.28% | -7.27% | 0.05% | 13.16% | 2.83% | 15.97% | 14.58% | 12.73% | 15.80% | 16.71% | 11.52% |
| Operating Income | 123.67M | -226.01M | -317.44M | -450.46M | -103.68M | -4.26B | 939.76M | 748.32M | 376.53M | 362.17M | 215.94M | 52.68M |
| Operating Income Ratio | 8.40% | -14.72% | -20.36% | -20.21% | -1.49% | -76.40% | 12.15% | 11.63% | 9.61% | 12.86% | 13.35% | 8.82% |
| Total Other Income/Expenses | -83.30M | -58.60M | -477.95M | -1.08B | -1.58B | -403.10M | -350.47M | -308.03M | -124.37M | -69.61M | -29.82M | -46.12M |
| Income Before Tax | 40.37M | -284.61M | -795.39M | -1.53B | -959.14M | -4.63B | 564.04M | 440.88M | 251.65M | 292.56M | 186.12M | 6.56M |
| Income Before Tax Ratio | 2.74% | -18.54% | -51.00% | -68.67% | -13.77% | -83.09% | 7.29% | 6.85% | 6.42% | 10.39% | 11.50% | 1.10% |
| Income Tax Expense | -1.20M | 1.64M | -37.30M | 85.35M | -56.57M | 122.99M | 68.47M | 62.58M | 61.57M | 82.58M | 45.95M | 5.09M |
| Net Income | 41.57M | 75.32M | 449.20M | -1.09B | -1.00B | -4.67B | 277.17M | 283.13M | 158.73M | 209.84M | 137.76M | 9.48M |
| Net Income Ratio | 2.82% | 4.91% | 28.80% | -48.94% | -14.37% | -83.78% | 3.58% | 4.40% | 4.05% | 7.45% | 8.51% | 1.59% |
| EPS | 0.07 | -0.45 | -1.15 | -2.24 | -2.07 | -9.66 | 0.59 | 0.68 | 0.56 | 0.78 | 0.63 | 0.04 |
| EPS Diluted | 0.07 | -0.45 | -1.15 | -2.24 | -2.07 | -9.66 | 0.59 | 0.68 | 0.56 | 0.78 | 0.63 | 0.04 |
| Weighted Avg Shares Out | 626.05M | 606.24M | 488.36M | 487.45M | 483.42M | 483.42M | 467.71M | 417.42M | 277.86M | 263.58M | 212.24M | 234.43M |
| Weighted Avg Shares Out (Dil) | 626.05M | 606.24M | 488.36M | 487.45M | 483.42M | 483.42M | 467.71M | 417.42M | 281.30M | 270.32M | 217.65M | 234.43M |
Source: https://incomestatements.info
Category: Stock Reports